# A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

> **NCT00552344** · PHASE3 · COMPLETED · sponsor: **UCB BIOSCIENCES GmbH** · enrollment: 403 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **BIOLOGICAL:** Cimzia

## Key facts

- **NCT ID:** NCT00552344
- **Lead sponsor:** UCB BIOSCIENCES GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 403 (ACTUAL)
- **Last updated:** 2018-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00552344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00552344, "A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00552344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*